Advancing development of medical countermeasures: Incorporating COVID-19 lessons learned into future pandemic preparedness planning

References

• Biomedical Advanced Research and Development Authority (BARDA). BARDA’s expanding COVID-19 medical countermeasure Portfolio. Washington (DC): U.S. Department of Health & Human Services, Administration for Strategic Preparedness and Response, BARDA; 2022 Aug 3 [accessed 2022 Sep 1]. https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx.
   Google Scholar
• Biomedical Advanced Research and Development Authority (BARDA). BARDA’s strategic plan: 2022–2026. Washington (DC): U.S. Department of Health & Human Services, Administration for Strategic Preparedness and Response, BARDA; 2022 May 24 [accessed 2022 Jul 28]. https://www.medicalcountermeasures.gov/media/38717/barda-strategic-plan-2022-2026.pdf.
   Google Scholar
• Tada T, Zhou H, Dcosta BM, Samanovic MI, Chivukula V, Herati RS, Hubbard SR, Mulligan MJ, Landau NR. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. eBiomed. 2022;78:1. PMID: 35465948. doi:10.1016/j.ebiom.2022.103944.
   Web of Science ®Google Scholar
• Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021;589(7840):16–6. PMID: 33340018. doi:10.1038/d41586-020-03626-1.
   PubMed Web of Science ®Google Scholar
• United States Government Accountability Office. Operation warp speed: accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges. Washington (DC): United States Government Accountability Office; 2021. Report No. GAO-21-319.
   Google Scholar
• Slaoui M, Hepburn M. Developing safe and effective Covid vaccines - operation warp speed’s strategy and approach. N Engl J Med. 2020;383(18):1701–03. PMID: 32846056. doi:10.1056/NEJMp2027405.
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools. Rockville (MD): U.S. Department of Health & Human Services, National Institutes of Health, NIAID; 2020 Jul 8 [accessed 2022 Sep 1]. https://www.niaid.nih.gov/news-events/nih-launches-clinical-trials-network-test-covid-19-vaccines-and-other-prevention-tools.
   Google Scholar
• Biomedical Advanced Research and Development Authority (BARDA). Global collaboration with BARDA scientists successfully develop Ebola countermeasures. Washington (DC): U.S. Department of Health & Human Services, Administration for Strategic Preparedness and Response, BARDA. 2021 Jun 21 [accessed 2022 Sep 1]. https://www.medicalcountermeasures.gov/stories/ebola-story/.
   Google Scholar
• Cox B. As emergent partnership dissolves, BARDA looks to revamp post-COVID pandemic preparedness. Pink Sheet; 2021 Nov 7 [accessed 2022 Jul 28]. https://pink.pharmaintelligence.informa.com/PS145210/As-Emergent-Partnership-Dissolves-BARDA-Looks-To-Revamp-PostCOVID-Pandemic-Preparedness.
   Google Scholar
• Kapoor K, Bigdeli A, Dwivedi Y, Raman R. How is COVID-19 altering the manufacturing landscape? A literature review of imminent challenges and management interventions. Ann Oper Res. 2021 Nov 17:33 [accessed 2022 Jul 28]. PMID: 34803204. doi:10.1007/s10479-021-04397-2.
   Web of Science ®Google Scholar
• Angelastro M, Johnson RA. COVID-19 vaccine supply chain management: a US perspective. Vaccine Insights. 2022;1(1):71–77. doi:10.18609/vac.2022.012.
   Google Scholar
• Rubin R. COVID-19 testing moves out of the clinic and into the home. JAMA. 2021;326(14):1362–64. PMID: 34550303. doi:10.1001/jama.2021.15679.
   PubMed Web of Science ®Google Scholar
• Walker M. Injectable sotrovimab offers another route for COVID treatment. MedPage Today; [accessed 2022 Jul 28]. https://www.medpagetoday.com/meetingcoverage/croi/97259.
   Google Scholar
• As of June 22, 2022, 78.1% of the US population had received at least one dose and 66.8% were fully vaccinated. However, only 47.2% of the US population had received a first booster dose, and only 25.3% received a second booster dose. See: Centers for Disease Control and Prevention (CDC). COVID data tracker. Atlanta (GA): U.S. Department of Health & Human Services, CDC; 2022 Jun 22 [accessed 2022 Jun 22]. https://covid.cdc.gov/covid-data-tracker.
   Google Scholar
• Siegel R. Classification of human viruses. In: Long S, editor. Principles and practice of pediatric infectious diseases. 5th ed. Philadelphia (PA): Elsevier; 2018. p. 1044–8.e1. doi:10.1016/B978-0-323-40181-4.00201-2.
   Google Scholar
• Zhang Z, Cai Z, Tan Z, Lu C, Jiang T, Zhang G, Peng Y. Rapid identification of human-infecting viruses. Transbound Emerg Dis. 2019;66(6):2517–22. PMID: 31373773. doi:10.1111/tbed.13314.
   PubMed Web of Science ®Google Scholar
• The White House. American pandemic preparedness: transforming our capabilities. Washington (DC): Executive Office of the President; 2021 Sep 3 [accessed 2022 Jul 28]. https://www.whitehouse.gov/wp-content/uploads/2021/09/American-Pandemic-Preparedness-Transforming-Our-Capabilities-Final-For-Web.pdf.
   Google Scholar
• Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104. PMID: 33341119. doi:10.1186/s12929-020-00695-2.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). 2009 H1N1 pandemic timeline. Atlanta (GA): U.S. Department of Health & Human Services, CDC; 2019 May 8 [accessed 2022 Sep 1]. https://www.cdc.gov/flu/pandemic-resources/2009-pandemic-timeline.html.
   Google Scholar
• Biomedical Advanced Research and Development Authority (BARDA). FDA approvals, licensures & clearances for BARDA supported products. Washington (DC): U.S. Department of Health & Human Services, Administration for Strategic Preparedness and Response, BARDA; 2022 May 19 [accessed 2022 Sep 1]. https://www.medicalcountermeasures.gov/barda/fdaapprovals.
   Google Scholar
• Relative investment estimate is based on a single product that achieves licensure (i.e., excludes costs for failed products). See: Farid SS, Baron M, Stamatis C, Nie W, Coffman J. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. MAbs. 2020;12(1):1754999. PMID: 32449439. doi:10.1080/19420862.2020.1754999.
   PubMed Web of Science ®Google Scholar